Soparkar Peter

CHIEF OPERATING OFFICER

Soparkar Peter has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company, with disclosures dating back to 2025. 2 of those filings fall inside the rolling window. Most recent filing: Dec 10, 2025.

On the most recent filing, Soparkar Peter is listed as CHIEF OPERATING OFFICER at Adverum Biotechnologies, Inc. Inside the rolling window, Soparkar Peter reported 1 open-market purchase totaling $211K in ADVM and no open-market sales.

Companies traded

Other insiders at ADVM

Insider Buying

$211K

reported purchases (SEC code P)

Insider Selling

$0

reported sales (SEC code S)

Companies

1

in the rolling window

Source
ADVMPurchase$211KDec 8SEC ↗
Showing 1–1 of 1
1 / 1

Frequently asked questions

How many SEC Form 4 filings has Soparkar Peter made?

Soparkar Peter has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company since 2025.

Which companies does Soparkar Peter trade?

Soparkar Peter has filed SEC Form 4 disclosures for 1 company, including ADVM.

When was Soparkar Peter's most recent SEC Form 4 filing?

Soparkar Peter's most recent SEC Form 4 filing on Tracefour is dated Dec 10, 2025.

What is Soparkar Peter's job title?

On the most recent SEC Form 4 filings tracked by Tracefour, Soparkar Peter is listed as CHIEF OPERATING OFFICER.

What is Soparkar Peter's total buy and sell value in the current window?

Inside the rolling retention window, Soparkar Peter bought $211K and sold $0 based on SEC Form 4 filings.

What was Soparkar Peter's largest disclosed transaction?

The largest disclosed transaction in the current window is a purchase of 50,000 ADVM shares on 2025-12-05, worth $211K, per SEC Form 4 filings.